BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• BioNTech SE has received an average rating of "Moderate Buy" from 14 brokerage firms, with a consensus 12-month price target of $134.32.
• Recent analyst ratings include a price objective cut by Morgan Stanley and a price increase by Bank of America, underscoring varied perceptions about the company's stock value.
• The company reported a quarterly revenue of $306.46 million, significantly surpassing analysts' expectations, although earnings per share fell short of estimates.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $134.3171.

BNTX has been the topic of several recent analyst reports. Morgan Stanley decreased their price objective on shares of BioNTech from $133.00 to $131.00 and set an "overweight" rating on the stock in a research report on Friday, October 10th. Wells Fargo & Company set a $150.00 price objective on shares of BioNTech and gave the company an "overweight" rating in a research report on Tuesday, August 5th. Bank of America raised their price objective on shares of BioNTech from $126.00 to $134.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of BioNTech in a research report on Tuesday. Finally, HC Wainwright reiterated a "buy" rating and issued a $136.00 price target on shares of BioNTech in a report on Monday, September 8th.

Institutional Trading of BioNTech

A number of institutional investors and hedge funds have recently bought and sold shares of BNTX. Goodman Advisory Group LLC bought a new stake in BioNTech in the 1st quarter valued at $105,000. Vontobel Holding Ltd. increased its holdings in shares of BioNTech by 2.3% in the 1st quarter. Vontobel Holding Ltd. now owns 21,882 shares of the company's stock worth $1,993,000 after buying an additional 497 shares during the last quarter. OneDigital Investment Advisors LLC bought a new stake in shares of BioNTech in the 1st quarter worth about $288,000. GF Fund Management CO. LTD. increased its holdings in shares of BioNTech by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,514 shares of the company's stock worth $229,000 after buying an additional 453 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of BioNTech by 18,892.9% in the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after buying an additional 694,691 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Trading Up 0.1%

Shares of BioNTech stock opened at $105.14 on Friday. The company's fifty day simple moving average is $103.76 and its 200-day simple moving average is $103.88. The stock has a market capitalization of $25.28 billion, a PE ratio of -65.71 and a beta of 1.45. BioNTech has a 1-year low of $81.20 and a 1-year high of $129.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The business had revenue of $306.46 million for the quarter, compared to analysts' expectations of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company's revenue was up 102.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that BioNTech will post -3.88 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.